L Pan1, F Ren, M Rong, Y Dang, Y Luo, D Luo, G Chen. 1. Department of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, 6 Shuangyong Road, Nanning, 530021, Guangxi Zhuang Autonomous Region, People's Republic of China.
Abstract
BACKGROUND AND AIMS: Researches have shown that miRNAs have been proposed as novel diagnostic biomarkers for classification and prognostic stratification of HCC. However, whether or not miR-431 contributes to the progression of HCC remains unknown. Therefore, we aimed to investigate the clinicopathological significance of miR-431 in HCC. METHODS: MiR-431 expression in 95 HCC cases and corresponding adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Furthermore, statistical analysis was performed to identify the correlations between expression of miR-431 and a variety of clinicopathological parameters and patient recurrence. The area under the receiver operating characteristic curve (AUC) was used to evaluate the accuracy of miR-431 as a biomarker for HCC diagnosis and prediction of disease deterioration. RESULTS: MiR-431 was markedly down-regulated in the HCC samples (1.1885 ± 0.75867) compared with corresponding adjacent tumor tissues (1.7957 ± 0.89333, P < 0.001). The AUC of low miR-431 expression to diagnose HCC was 0.668 (95 % CI 0.592-0.744, P < 0.001). MiR-431 down-expression was correlated with multiple malignant characteristics, including lymph node metastasis (r = -0.455, P < 0.001), clinical TNM stage (r = -0.223, P = 0.030), MTDH (r = -0.292, P = 0.006), vaso-invasion (r = -0.204, P = 0.047), MVD (r = -0.281, P = 0.006) and HCV (r = 0.215, P = 0.037). Additionally, the recurrent time of lower miR-431 expression group was 56.602 ± 3.914 months, much longer than that in the high expression group (50.009 ± 2.731 months), however, no significant difference was noted (χ (2) = 0.005, P = 0.943). CONCLUSIONS: The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
BACKGROUND AND AIMS: Researches have shown that miRNAs have been proposed as novel diagnostic biomarkers for classification and prognostic stratification of HCC. However, whether or not miR-431 contributes to the progression of HCC remains unknown. Therefore, we aimed to investigate the clinicopathological significance of miR-431 in HCC. METHODS:MiR-431 expression in 95 HCC cases and corresponding adjacent non-cancerous tissues was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR). Furthermore, statistical analysis was performed to identify the correlations between expression of miR-431 and a variety of clinicopathological parameters and patient recurrence. The area under the receiver operating characteristic curve (AUC) was used to evaluate the accuracy of miR-431 as a biomarker for HCC diagnosis and prediction of disease deterioration. RESULTS:MiR-431 was markedly down-regulated in the HCC samples (1.1885 ± 0.75867) compared with corresponding adjacent tumor tissues (1.7957 ± 0.89333, P < 0.001). The AUC of low miR-431 expression to diagnose HCC was 0.668 (95 % CI 0.592-0.744, P < 0.001). MiR-431 down-expression was correlated with multiple malignant characteristics, including lymph node metastasis (r = -0.455, P < 0.001), clinical TNM stage (r = -0.223, P = 0.030), MTDH (r = -0.292, P = 0.006), vaso-invasion (r = -0.204, P = 0.047), MVD (r = -0.281, P = 0.006) and HCV (r = 0.215, P = 0.037). Additionally, the recurrent time of lower miR-431 expression group was 56.602 ± 3.914 months, much longer than that in the high expression group (50.009 ± 2.731 months), however, no significant difference was noted (χ (2) = 0.005, P = 0.943). CONCLUSIONS: The down-expression of miR-431 is partially responsible for a series of clinicopathological features which may be tightly correlated with the progression of HCC. Thus, expression of miR-431 may be proposed as a new factor in association with the progression of HCC.
Authors: Jong-Kook Park; Takayuki Kogure; Gerard J Nuovo; Jinmai Jiang; Lei He; Ji Hye Kim; Mitch A Phelps; Tracey L Papenfuss; Carlo M Croce; Tushar Patel; Thomas D Schmittgen Journal: Cancer Res Date: 2011-10-18 Impact factor: 12.701
Authors: Joacim Elmén; Morten Lindow; Sylvia Schütz; Matthew Lawrence; Andreas Petri; Susanna Obad; Marie Lindholm; Maj Hedtjärn; Henrik Frydenlund Hansen; Urs Berger; Steven Gullans; Phil Kearney; Peter Sarnow; Ellen Marie Straarup; Sakari Kauppinen Journal: Nature Date: 2008-03-26 Impact factor: 49.962
Authors: Jun Lu; Gad Getz; Eric A Miska; Ezequiel Alvarez-Saavedra; Justin Lamb; David Peck; Alejandro Sweet-Cordero; Benjamin L Ebert; Raymond H Mak; Adolfo A Ferrando; James R Downing; Tyler Jacks; H Robert Horvitz; Todd R Golub Journal: Nature Date: 2005-06-09 Impact factor: 49.962
Authors: Kawther Abu-Elneel; Tsunglin Liu; Francesca S Gazzaniga; Yuhei Nishimura; Dennis P Wall; Daniel H Geschwind; Kaiqin Lao; Kenneth S Kosik Journal: Neurogenetics Date: 2008-06-19 Impact factor: 2.660
Authors: Ahmed M Salem; Samira Ismail; Waheba A Zarouk; Olwya Abdul Baky; Ahmed A Sayed; Sawsan Abd El-Hamid; Sohair Salem Journal: ScientificWorldJournal Date: 2013-12-23
Authors: Gang Chen; Ijeoma Adaku Umelo; Shasha Lv; Erik Teugels; Karel Fostier; Peter Kronenberger; Alex Dewaele; Jan Sadones; Caroline Geers; Jacques De Grève Journal: PLoS One Date: 2013-03-26 Impact factor: 3.240
Authors: Haruhiro Yamashita; Sailesh Surapureddi; Ramesh C Kovi; Sachin Bhusari; Thai Vu Ton; Jian-Liang Li; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; Cynthia V Rider; Mark J Hoenerhoff; Robert C Sills; Arun R Pandiri Journal: Arch Toxicol Date: 2020-04-18 Impact factor: 5.153